Kamada (KMDA) Return on Capital Employed (2018 - 2026)
Kamada (KMDA) posted quarterly Return on Capital Employed of 5903.87% for Q1 2026, up 589349.0% year-on-year from N/an in Q1 2025, and up 2.95% on a QoQ basis from 5734.87% in Q4 2025.
Kamada (KMDA) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kamada (KMDA) has reported Return on Capital Employed for 9 consecutive years, with 5903.87% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed rose 589349.0% year-over-year to 5903.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5903.87% (up 589349.0% YoY) and the FY2025 annual result came in at 8.0%, up 798.0% from the prior year.
- Return on Capital Employed grew to 5903.87% in Q1 2026 per KMDA's latest filing, from 5734.87% in the prior quarter.
- Over the last five years, Return on Capital Employed for KMDA reached as high as 5903.87% in Q1 2026 and fell as low as 2.42% in Q2 2022.
- A 5-year average of 1685.56% and a median of 819.92% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 104388 bps — and 2026, when it soared 589349 bps.
- Year by year, Return on Capital Employed stood at 1045.23% in 2022, then slumped by 100 bps to 1.35% in 2023, then jumped by 592 bps to 9.32% in 2024, then soared by 61417 bps to 5734.87% in 2025, then grew by 3 bps to 5903.87% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 5903.87%, 5734.87%, and 5836.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 5,903.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,903.87% |
| Dec 31, 2025 | 5,734.87% |
| Sep 30, 2025 | 5,836.08% |
| Jun 30, 2025 | 5,817.20% |
| Mar 31, 2025 | 10.38% |
| Dec 31, 2024 | 9.32% |
| Sep 30, 2024 | 7.02% |
| Jun 30, 2024 | 1,430.54% |
| Mar 31, 2024 | 2.46% |
| Dec 31, 2023 | 1.35% |
| Sep 30, 2023 | 2.77% |
| Jun 30, 2023 | 1,144.13% |
| Mar 31, 2023 | 892.82% |
| Dec 31, 2022 | 1,045.23% |
| Sep 30, 2022 | 819.92% |
| Jun 30, 2022 | -2.42% |
| Mar 31, 2022 | -1.05% |
| Dec 31, 2021 | 0.20% |
| Sep 30, 2021 | 4.01% |
| Jun 30, 2021 | 9.27% |